Uric Acid-Lowering Therapy May Increase Risk for CKD
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
Hyperuricemia
SGLT2 Inhibitors Shown to Increase Uric Acid Excretion
Increased uric acid excretion could explain, at least in part, the renoprotective effects of SGLT2 inhibitors.
Colchicine May Lower Risk of CKD Progression
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
Pegloticase Plus Methotrexate Gets Priority Review for Uncontrolled Gout
The sBLA submission is supported by data from the phase 4 MIRROR trial.
Horizon Seeks Approval of Pegloticase Plus Methotrexate for Uncontrolled Gout
The sBLA submission is supported by data from the phase 4 MIRROR trial.
Urate-Degrading Enzyme Fast Tracked for Hyperuricemia With Gout and CKD
ALLN-346 is an investigational, first-in-class, nonabsorbed, orally-administered enzyme that breaks down urate in the gastrointestinal tract.
Response to Pegloticase Therapy Improved With Concomitant Methotrexate
The double-blind, placebo-controlled MIRROR trial included 152 adults with uncontrolled gout.
Urate-Lowering Therapy Associated With Decreased Gout Flare Risk
Patients with asymptomatic hyperuricemia who achieved serum uric acid levels of 6.0 mg/dL or less while on urate-lowering therapy had fewer gout flare episodes, a study found.
Pegloticase Use for Uncontrolled Gout in the Dialysis Population Described
New study is the first to characterize pegloticase use in the dialysis population.
No Increased Cardiovascular Risk With Febuxostat vs Allopurinol
In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout.
